Patents by Inventor Chuan-Chu Chou

Chuan-Chu Chou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
    Publication number: 20240124580
    Abstract: The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs.
    Type: Application
    Filed: December 27, 2023
    Publication date: April 18, 2024
    Inventors: Wang ZHANG, Shu WU, Shuai YANG, Qi PAN, Chuan-Chu CHOU
  • Single-domain antibodies against LAG-3 and uses thereof
    Patent number: 11958903
    Abstract: The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: April 16, 2024
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Wang Zhang, Shuai Yang, Shu Wu, Chuan-Chu Chou
  • Single-domain antibodies and variants thereof against TIGIT
    Patent number: 11905327
    Abstract: Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: February 20, 2024
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Wang Zhang, Shu Wu, Shuai Yang, Qi Pan, Chuan-Chu Chou
  • BISPECIFIC ANTIBODY FOR CLAUDIN 18A2 AND CD3 AND APPLICATION OF BISPECIFIC ANTIBODY
    Publication number: 20240010748
    Abstract: A bispecific antibody directed against Claudin 18.2 and CD3, pharmaceutical compositions including the bispecific antibody, and a use thereof in the treatment of cancer are provided. The bispecific antibody includes an anti-CLDN18.2 binding domain and an anti-CD3 binding domain, the first binding domain being capable of binding to a CLDN18.2 protein, the second binding domain being capable of binding to CD3.
    Type: Application
    Filed: November 10, 2021
    Publication date: January 11, 2024
    Applicant: SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD.
    Inventors: Jiahua JIANG, Xiao LUO, Jinming GU, Chuan-Chu CHOU, Shihao CHEN, Yingying YANG
  • Single-domain antibodies and variants thereof against PD-1
    Patent number: 11713353
    Abstract: Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-1. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: August 1, 2023
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Yafeng Zhang, Shu Wu, Shuai Yang, Chuan-Chu Chou
  • Antibodies and variants thereof against TIGIT
    Patent number: 11708410
    Abstract: The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes TIGIT. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: July 25, 2023
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Xinpo Jiang, Shuai Yang, Chuan-Chu Chou
  • Single-domain antibodies and variants thereof against PD-L1
    Patent number: 11673954
    Abstract: The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-L1. Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 13, 2023
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Yafeng Zhang, Shu Wu, Shuai Yang, Chuan-Chu Chou
  • MULTISPECIFIC ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20230059836
    Abstract: Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.
    Type: Application
    Filed: August 10, 2022
    Publication date: February 23, 2023
    Inventors: Chuan-Chu CHOU, Yafeng ZHANG, Shu WU, Zhenyu LIU, Zhongdao LI, Fangliang ZHANG
  • Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum
    Patent number: 11505601
    Abstract: Novel antibodies, such as single domain antibodies (sdAbs), or antigen-binding fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are also described.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: November 22, 2022
    Assignee: Nanjing Legend Biotech Co., Ltd
    Inventors: Yafeng Zhang, Shu Wu, Fei Sun, Shuai Yang, Chuan-Chu Chou
  • Single-domain antibodies and variants thereof against CTLA-4
    Patent number: 11472881
    Abstract: The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Also provided are methods of making and using these constructs.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 18, 2022
    Assignee: NANJING LEGEND BIOTECH CO., LTD.
    Inventors: Yafeng Zhang, Shu Wu, Shuai Yang, Chuan-Chu Chou
  • Multispecific antigen binding proteins and methods of use thereof
    Patent number: 11447573
    Abstract: Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: September 20, 2022
    Assignee: NANJING LEGEND BIOTECH CO., LTD.
    Inventors: Chuan-Chu Chou, Yafeng Zhang, Shu Wu, Zhenyu Liu, Zhongdao Li, Fangliang Zhang
  • ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1
    Publication number: 20220135687
    Abstract: The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes PD-L1. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen binding fragment thereof.
    Type: Application
    Filed: December 28, 2018
    Publication date: May 5, 2022
    Inventors: Shuai Yang, Chuan-Chu Chou, Shu Wu, Liusong Yin, Feng Lin
  • COMPOSITIONS AND METHODS FOR INCREASING PROTEIN HALF-LIFE IN A SERUM
    Publication number: 20220033481
    Abstract: Novel antibodies, such as single domain antibodies (sdAbs), or antigen-binding fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are also described.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 3, 2022
    Inventors: Yafeng ZHANG, Shu WU, Fei SUN, Shuai YANG, Chuan-Chu CHOU
  • CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210261675
    Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 26, 2021
    Applicant: Legend Biotech USA Inc.
    Inventors: Xiaohu FAN, Chuan-Chu CHOU, Qiuchuan ZHUANG, Pingyan WANG, Lin WANG, Lei YANG, Jiaying HAO
  • SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1
    Publication number: 20210221891
    Abstract: The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-L1. Also provided are methods of making and using these constructs.
    Type: Application
    Filed: November 13, 2018
    Publication date: July 22, 2021
    Inventors: Yafeng ZHANG, Shu WU, Shuai YANG, Chuan-Chu CHOU
  • ANTI-CD47 ANTIBODIES THAT DO NOT CAUSE SIGNIFICANT RED BLOOD CELL AGLLUTINATION
    Publication number: 20210070855
    Abstract: Provided are antibodies including monoclonal, human, primate, rodent, mammalian, chimeric, humanized and CDR-grafted antibodies, and antigen binding fragments and antigen binding derivatives thereof. These antibodies bind to CD47 protein, particularly human CD47, modulate, e.g., inhibit, block, antagonize, neutralize or otherwise interfere with CD47 expression, activity and/or signaling, including inhibiting CD47 and SIRPa interaction; do not cause a significant level of hemagglutination of human red blood cells. These antibodies may not enhance RBC phagocytosis.
    Type: Application
    Filed: January 24, 2019
    Publication date: March 11, 2021
    Inventors: Tao Zhao, Huihui Zhang, Shuai Yang, Yun Zhang, Chuan-Chu Chou, Shu Wu
  • Chimeric antigen receptors based on single domain antibodies and methods of use thereof
    Patent number: 10934363
    Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 2, 2021
    Assignee: Legend Biotech USA Inc.
    Inventors: Xiaohu Fan, Chuan-Chu Chou, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao
  • SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
    Publication number: 20210054071
    Abstract: Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs.
    Type: Application
    Filed: December 28, 2018
    Publication date: February 25, 2021
    Inventors: Wang ZHANG, Shu WU, Shuai YANG, Qi PAN, Chuan-Chu CHOU
  • SINGLE-DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF
    Publication number: 20210017279
    Abstract: The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.
    Type: Application
    Filed: March 29, 2019
    Publication date: January 21, 2021
    Inventors: Wang Zhang, Shuai YANG, Shu WU, Chuan-Chu CHOU
  • MULTISPECIFIC ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20200369770
    Abstract: Provided are multispecific, such as trispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, a second antigen binding domain comprising a first single-domain antibody, and a third antigen binding domain comprising a second single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.
    Type: Application
    Filed: January 8, 2019
    Publication date: November 26, 2020
    Inventors: Yafeng ZHANG, Chuan-Chu CHOU, Qi PAN, Shu WU, Shuai YANG